Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Syndax’s revumenib meets primary results in AML trial
Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia, or ...
Treatment target for aggressive leukemia discovered by disrupting its genome organization
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...